G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023
RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: ), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year 2022 on Wednesday, March 1, 2023, at 8:30 a.m. ET.
Please note that there is a new process to access the call via telephone. To register and receive a dial in number and unique PIN to access the live conference call, please follow this to . While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the page of the company’s website: . The webcast will be archived on the same page for 90 days following the event.
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit and follow us on Twitter @G1Therapeutics.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc.
G1 Therapeutics Contacts:
Will Roberts
Vice President
Investor Relations and Corporate Communications
(919) 907-1944
Rebecca Levine
Director, Corporate Communications and Public Relations
(919) 667-8711
